

Nano-Biosensors for Early Diagnosis and Continuous Monitoring of Obesity-Linked Metabolic Disorders

Kato Jumba K.

Faculty of Science and Technology Kampala International University Uganda

ABSTRACT

Obesity is a key risk factor for several metabolic disorders, including type 2 diabetes (T2D), cardiovascular diseases, and fatty liver disease. Early diagnosis and continuous monitoring of these conditions are crucial for timely intervention and prevention of further complications. Nano-biosensors, leveraging the unique properties of nanomaterials, offer a promising solution for early detection and real-time monitoring of obesity-linked metabolic disorders. These sensors can detect specific biomarkers related to insulin resistance, inflammation, lipid metabolism, and glucose homeostasis with high sensitivity and selectivity. This review explores the principles, types, and applications of nano-biosensors for diagnosing and monitoring obesity-related metabolic disorders. It also discusses the challenges and future directions for integrating nano-biosensors into clinical practice for improved patient management and personalized therapy.

Keywords: nano-biosensors, obesity, metabolic disorders, early diagnosis, continuous monitoring

INTRODUCTION

Obesity has become a global epidemic, with the World Health Organization (WHO) reporting over 650 million adults affected by obesity worldwide. It is a major contributing factor to various metabolic disorders such as type 2 diabetes (T2D), cardiovascular diseases (CVD), non-alcoholic fatty liver disease (NAFLD), and insulin resistance (IR)[1–5]. Obesity-induced insulin resistance, characterized by impaired insulin signaling, is a key feature of T2D and is associated with chronic low-grade inflammation, dysregulated lipid metabolism, and altered glucose homeostasis[4, 6–9]. Early diagnosis and continuous monitoring of these metabolic abnormalities are essential for managing and preventing obesity-linked complications.

Current diagnostic approaches for obesity-related metabolic disorders mainly involve clinical assessments such as blood glucose tests, lipid profiles, insulin resistance markers, and imaging techniques[10–12]. While these methods are effective, they are often limited by invasive procedures, delayed detection, and the inability to provide continuous real-time monitoring of disease progression[12]. Additionally, existing diagnostic techniques often do not capture the early molecular changes associated with metabolic disorders, leading to delayed interventions.

Recent advances in nanotechnology have led to the development of nano-biosensors devices capable of detecting specific biomarkers at extremely low concentrations with high sensitivity and selectivity[13]. These sensors leverage the unique properties of nanomaterials, such as high surface area, nanoscale size, and tunable surface chemistry, to enhance detection capabilities. Nano-biosensors can be integrated into wearable devices, smartphones, and implantable systems, enabling real-time continuous monitoring of biomarkers associated with insulin resistance, inflammation, oxidative stress, and lipid metabolism[14, 15].

The application of nano-biosensors in diagnosing and monitoring obesity-linked metabolic disorders offers several advantages, including early detection, minimally invasive sampling, continuous monitoring, and personalized management[16–18]. By detecting specific biomarkers related to metabolic dysfunctions, nano-biosensors can identify individuals at risk before clinical symptoms manifest, allowing for earlier interventions and more effective disease management.

This review explores the role of nano-biosensors in the early diagnosis and continuous monitoring of obesity-linked metabolic disorders, highlighting the types of sensors, the biomarkers they target, and their clinical applications. Additionally, the review discusses the challenges of integrating nano-biosensors into clinical practice and the future directions for their development and widespread use in personalized healthcare.

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<http://creativecommons.org/licenses/by/4.0>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited

2. Types of Nano-Biosensors for Metabolic Monitoring

Nano-biosensors are broadly classified into electrochemical, optical, piezoelectric, and thermal sensors, each of which utilizes different detection principles to monitor metabolic biomarkers. These sensors are designed to operate on a nanoscale level, offering high sensitivity, low detection limits, and rapid response times.

Electrochemical Nano-Biosensors

Electrochemical nano-biosensors are among the most widely used sensors for metabolic monitoring due to their high sensitivity, cost-effectiveness, and ease of integration with portable devices[19, 20]. These sensors typically consist of a nanomaterial-based electrode that interacts with target biomarkers to produce an electrochemical signal (current, voltage, or impedance). The key advantage of electrochemical sensors is their ability to detect biomarkers at extremely low concentrations (picomolar or nanomolar range)[20].

Glucose monitoring is one of the most common applications of electrochemical nano-biosensors in metabolic disorders[21]. These sensors utilize glucose oxidase or glucose dehydrogenase enzymes that catalyze the oxidation of glucose, producing hydrogen peroxide, which can be detected electrochemically. In addition to glucose, electrochemical nano-biosensors have been designed to detect insulin, lipid markers, and inflammatory cytokines, all of which are critical in the pathophysiology of obesity and its associated metabolic disorders[21].

Optical Nano-Biosensors

Optical nano-biosensors operate by detecting changes in light absorption, scattering, or fluorescence caused by interactions between the sensor and target biomarkers. These sensors often use gold nanoparticles, quantum dots, or carbon nanotubes as the detection platform. Optical sensors are known for their high sensitivity, especially in detecting small molecules and protein biomarkers associated with metabolic diseases[22, 23].

For example, optical nano-biosensors have been developed to detect lipid peroxidation products, free fatty acids, and adipokines, which are involved in obesity-induced inflammation and insulin resistance[24]. Surface plasmon resonance (SPR) and fluorescence resonance energy transfer (FRET) are commonly used in optical biosensors to detect binding interactions between nanoparticles and biomarkers, providing real-time, non-invasive monitoring of metabolic abnormalities[24].

Piezoelectric Nano-Biosensors

Piezoelectric nano-biosensors utilize changes in the mechanical properties of nanomaterials, such as carbon nanotubes or graphene, when they interact with target molecules[25]. These sensors measure shifts in resonance frequency caused by the binding of biomarkers to the surface of the sensor. Piezoelectric sensors are highly sensitive and can be used to detect proteins, lipids, and DNA in biological fluids[25, 26].

In the context of obesity-related metabolic disorders, piezoelectric nano-biosensors can be used to monitor insulin resistance and inflammatory markers by detecting changes in the concentration of cytokines or insulin signaling proteins in real-time[26].

Thermal Nano-Biosensors

Thermal nano-biosensors detect changes in heat production or thermal conductivity resulting from biochemical interactions between a biomarker and the sensing surface. These sensors can be applied to detect metabolic changes in lipid metabolism and oxidative stress, both of which are key factors in obesity-related metabolic disorders[27]. Although thermal nano-biosensors are still in the early stages of development, they hold promise for providing real-time data on fatty acid metabolism and energy expenditure, offering insights into how the body responds to metabolic changes in obesity[28, 29].

3. Biomarkers for Obesity-Linked Metabolic Disorders

The success of nano-biosensors in diagnosing and monitoring obesity-linked metabolic disorders relies on their ability to detect specific biomarkers that are indicative of metabolic dysfunctions. These biomarkers are often involved in key physiological processes such as insulin resistance, inflammation, lipid metabolism, and oxidative stress[30, 31].

Glucose and Insulin

One of the hallmark features of obesity-induced metabolic disorders is insulin resistance, which is characterized by a diminished response to insulin in peripheral tissues such as adipose tissue, muscle, and the liver[32]. Early detection of insulin resistance is critical for preventing the progression to type 2 diabetes. Nano-biosensors can monitor glucose levels and insulin in real-time, providing early indicators of metabolic dysregulation. Continuous monitoring of these biomarkers can help adjust insulin therapy and track the effectiveness of lifestyle interventions[32].

Inflammatory Cytokines

Chronic low-grade inflammation is a central feature of obesity-induced metabolic disorders. Key pro-inflammatory cytokines, such as TNF- α , IL-6, IL-1 β , and C-reactive protein (CRP), are elevated in obese individuals and contribute to insulin resistance and cardiovascular risk[33]. Nano-biosensors can detect these inflammatory markers with high specificity and sensitivity, allowing for early detection of systemic inflammation before overt clinical symptoms manifest[34].

Lipid Metabolism Markers

Disrupted lipid metabolism is another characteristic of obesity and insulin resistance. Elevated levels of free fatty acids, triglycerides, and lipid peroxidation products have been linked to the development of metabolic diseases such as type 2 diabetes, non-alcoholic fatty liver disease (NAFLD), and atherosclerosis[35]. Nano-biosensors can measure these lipid markers, providing a non-invasive and continuous way to monitor metabolic dysregulation in real-time[35].

Adipokines

Adipokines, including leptin, adiponectin, and resistin, are secreted by adipocytes and play crucial roles in regulating metabolic functions. Dysregulation of adipokine secretion is associated with obesity-induced insulin resistance and metabolic dysfunction[36]. Nano-biosensors can measure changes in the levels of these adipokines, providing valuable insights into the metabolic state of obese individuals and offering a means of tracking disease progression[36].

4. Applications of Nano-Biosensors in Metabolic Disorders

The application of nano-biosensors for diagnosing and monitoring obesity-related metabolic disorders holds significant potential for improving patient care and disease management[37]. These sensors can be integrated into wearable devices, implantable sensors, or smartphone apps, allowing for continuous and real-time monitoring of biomarkers associated with obesity, insulin resistance, and metabolic dysfunction[37].

Early Diagnosis

Early detection of obesity-related metabolic disorders is critical for preventing the progression to more severe conditions like type 2 diabetes and cardiovascular diseases[38]. Nano-biosensors can detect biomarkers associated with insulin resistance, inflammation, and lipid metabolism at very early stages, even before clinical symptoms appear. This allows for timely interventions, such as lifestyle modifications or pharmacological treatments, to prevent further disease progression[38].

Continuous Monitoring

Continuous monitoring of metabolic biomarkers is essential for managing obesity-linked diseases. Nano-biosensors can provide real-time data on glucose levels, insulin resistance, and inflammatory markers, allowing for more precise adjustments to treatment plans[39, 40]. For example, wearable glucose sensors, such as continuous glucose monitoring (CGM) systems, can help individuals with obesity track their blood glucose levels throughout the day and make necessary changes to their diet, exercise, or insulin therapy[40].

Personalized Medicine

Nano-biosensors offer the potential for personalized medicine, where treatment plans are tailored to an individual's unique metabolic profile[41, 42]. By continuously monitoring biomarkers, healthcare providers can adjust treatment protocols based on real-time data, optimizing therapeutic outcomes and reducing the risk of complications [43].

5. Challenges and Future Directions

While nano-biosensors offer great promise for the early diagnosis and continuous monitoring of obesity-related metabolic disorders, several challenges remain in their development and clinical application.

Biocompatibility and Safety

The biocompatibility of nano-biosensors is a major concern, particularly for long-term implantation or wearables. The potential for immune responses or toxicity due to nanoparticle accumulation in tissues must be carefully evaluated. Furthermore, the stability of sensors over time is essential to ensure consistent performance in real-world settings.

Integration into Clinical Practice

The successful integration of nano-biosensors into clinical practice requires overcoming challenges related to device miniaturization, power supply, and data interpretation. While wearable sensors are increasingly being developed, issues related to data accuracy, signal interference, and sensor calibration need to be addressed to ensure reliable results.

Cost and Accessibility

The widespread adoption of nano-biosensors for metabolic monitoring depends on their cost-effectiveness and accessibility. The development of low-cost sensors that provide accurate and real-time data is essential for making these technologies available to a broader population.

Future Directions

Future research should focus on improving the selectivity and sensitivity of nano-biosensors for detecting a broader range of biomarkers. Additionally, the development of multi-analyte sensors that can simultaneously monitor glucose, insulin, inflammatory markers, and lipid metabolism would enhance the utility of these devices in comprehensive metabolic monitoring. Integration with smartphones and cloud-based platforms could further enhance the accessibility and ease of use, enabling patients to track their health metrics in real-time.

CONCLUSION

Nano-biosensors offer a revolutionary approach for the early diagnosis and continuous monitoring of obesity-linked metabolic disorders. By detecting biomarkers related to insulin resistance, inflammation, lipid

metabolism, and glucose homeostasis, nano-biosensors enable real-time monitoring of metabolic dysfunctions with high sensitivity and selectivity. These sensors can be integrated into wearable devices, implantable systems, and smartphone apps, providing continuous data that can guide personalized treatment plans and improve patient outcomes. While challenges related to biocompatibility, cost, and integration into clinical practice remain, the potential of nano-biosensors to transform the management of obesity and its associated metabolic disorders is immense. As research progresses and technologies advance, nano-biosensors are expected to play an increasingly important role in the early detection, monitoring, and management of metabolic diseases, ultimately improving healthcare outcomes and reducing the burden of obesity-related complications.

REFERENCES

1. Acevedo-Román, A., Pagán-Zayas, N., Velázquez-Rivera, L.I., Torres-Ventura, A.C., Godoy-Vitorino, F.: Insights into Gut Dysbiosis: Inflammatory Diseases, Obesity, and Restoration Approaches. *Int. J. Mol. Sci.* 25, 9715 (2024). <https://doi.org/10.3390/ijms25179715>
2. Alum, E.U., Izah, S.C., Betiang, P.A., Paul-Chima Ugwu, O., Ainebyoona, C., Uti, D.E., Echegu, D.A., Alum, B.N.: The Ketogenic Diet in Obesity Management: Friend or Foe? *Cell Biochem. Biophys.* (2025). <https://doi.org/10.1007/s12013-025-01878-0>
3. Anand, S., Patel, T.N.: Integrating the metabolic and molecular circuits in diabetes, obesity and cancer: a comprehensive review. *Discov. Oncol.* 15, 779 (2024). <https://doi.org/10.1007/s12672-024-01662-1>
4. Annett, S., Moore, G., Robson, T.: Obesity and Cancer Metastasis: Molecular and Translational Perspectives. *Cancers.* 12, 3798 (2020). <https://doi.org/10.3390/cancers12123798>
5. Uti, D.E., Omang, W.A., Alum, E.U., Ugwu, O.P.-C., Wokoma, M.A., Oplekwu, R.I., Atangwho, I.J., Egbung, G.E.: Combined Hyaluronic Acid Nanobioconjugates Impair CD44-Signaling for Effective Treatment Against Obesity: A Review of Comparison with Other Actors. *Int. J. Nanomedicine.* 20, 10101–10126 (2025). <https://doi.org/10.2147/IJN.S529250>
6. Bhattacharya, S., Aggarwal, P., Bera, O.P., Saleem, S.M., Shikha, D., Vallabh, V., Juyal, R., Singh, A.: Covid-19 and Childhood Obesity (Co-Besity) in the Era of New Normal Life: A Need for a Policy Research. *J. Public Health Res.* 10, jphr.2021.2673 (2021). <https://doi.org/10.4081/jphr.2021.2673>
7. Bays, H.E., Kirkpatrick, C., Maki, K.C., Toth, P.P., Morgan, R.T., Tondt, J., Christensen, S.M., Dixon, D., Jacobson, T.A.: Obesity, dyslipidemia, and cardiovascular disease: A joint expert review from the Obesity Medicine Association and the National Lipid Association 2024. *Obes. Pillars.* 10, 100108 (2024). <https://doi.org/10.1016/j.obpill.2024.100108>
8. Uti, D.E., Ibiama, U.A., Omang, W.A., Udeozor, P.A., Umoru, G.U., Nwadium, S.K., Bawa, I., Alum, E.U., Mordi, J.C., Okoro, E.O., Obeten, U.N., Onwe, E.N., Zakari, S., Opotu, O.R., Aja, P.M.: *Buchholzia coriacea* Leaves Attenuated Dyslipidemia and Oxidative Stress in Hyperlipidemic Rats and Its Potential Targets In Silico. *Pharm. Fronts.* 05, e141–e152 (2023). <https://doi.org/10.1055/s-0043-1772607>
9. Atangwho, I.J., Ugwu, O.P.-C., Egbung, G.E., Aja, P.M.: Lipid-based nano-carriers for the delivery of anti-obesity natural compounds: advances in targeted delivery and precision therapeutics. *J. Nanobiotechnology.* 23, 336 (2025). <https://doi.org/10.1186/s12951-025-03412-z>
10. Kim, S.R., Lerman, L.O.: Diagnostic Imaging in the Management of Patients with Metabolic Syndrome. *Transl. Res. J. Lab. Clin. Med.* 194, 1–18 (2018). <https://doi.org/10.1016/j.trsl.2017.10.009>
11. Cianciosi, D., Armas Diaz, Y., Grosso, G., Quiles, J.L., Giampieri, F., Battino, M.: Association between diagnostic imaging and biochemical markers: a possible tool for monitoring metabolic disorders. *Curr. Opin. Food Sci.* 55, 101109 (2024). <https://doi.org/10.1016/j.cofs.2023.101109>
12. Zhan, S., Zhou, X., Fu, J.: Noninvasive Urinary Biomarkers for Obesity-Related Metabolic Diseases: Diagnostic Applications and Future Directions. *Biomolecules.* 15, 633 (2025). <https://doi.org/10.3390/biom15050633>
13. Baruah, A., Newar, R., Das, S., Kalita, N., Nath, M., Ghosh, P., Chinnam, S., Sarma, H., Narayan, M.: Biomedical applications of graphene-based nanomaterials: recent progress, challenges, and prospects in highly sensitive biosensors. *Discov. Nano.* 19, 103 (2024). <https://doi.org/10.1186/s11671-024-04032-6>
14. Upadhaya, A., Pegu, J., Singh, Y.D., Ngomle, S.: Nanoparticle-enabled portable biosensors for early detection and monitoring of non-communicable diseases: A focus on diabetes, cardiovascular, and cancer diagnostics. *Biosens. Bioelectron.* X, 26, 100675 (2025). <https://doi.org/10.1016/j.biosx.2025.100675>
15. Baranwal, A., Bansal, V., Shukla, R.: Emerging Biomarkers and Nanobiosensing Strategies in Diabetes. *Biosensors.* 15, 639 (2025). <https://doi.org/10.3390/bios15100639>
16. Gulati, S., Yadav, R., Kumari, V., Nair, S., Gupta, C., Aishwari, M.: Nanosensors in healthcare: transforming real-time monitoring and disease management with cutting-edge nanotechnology. *RSC Pharm.* 2, 1003–1018 (2025). <https://doi.org/10.1039/D5PM00125K>
17. Ramesh, M., Janani, R., Deepa, C., Rajeshkumar, L.: Nanotechnology-Enabled Biosensors: A Review of Fundamentals, Design Principles, Materials, and Applications. *Biosensors.* 13, 40 (2022). <https://doi.org/10.3390/bios13010040>

18. Kumari, M., Gupta, V., Kumar, N., Arun, R.K.: Microfluidics-Based Nanobiosensors for Healthcare Monitoring. *Mol. Biotechnol.* 66, 378–401 (2024). <https://doi.org/10.1007/s12033-023-00760-9>
19. Hassan, R.Y.A.: Advances in Electrochemical Nano-Biosensors for Biomedical and Environmental Applications: From Current Work to Future Perspectives. *Sensors.* 22, 7539 (2022). <https://doi.org/10.3390/s22197539>
20. Zhang, Q., Zhao, G., Wang, S., Song, Y., Sun, Y.: Polymer-Based Electrochemical Sensors for the Diagnosis of Neurodegenerative Diseases. *Cell. Mol. Neurobiol.* 45, 52 (2025). <https://doi.org/10.1007/s10571-025-01570-0>
21. Safarkhani, M., Aldhaher, A., Heidari, G., Zare, E.N., Warkiani, M.E., Akhavan, O., Huh, Y., Rabiee, N.: Nanomaterial-assisted wearable glucose biosensors for noninvasive real-time monitoring: Pioneering point-of-care and beyond. *Nano Mater. Sci.* 6, 263–283 (2024). <https://doi.org/10.1016/j.nanoms.2023.11.009>
22. Ahmad, M., Hasan, M., Tarannum, N., Hasan, M., Ahmed, S.: Recent advances in optical and photoelectrochemical nanobiosensor technology for cancer biomarker detection. *Biosens. Bioelectron. X.* 14, 100375 (2023). <https://doi.org/10.1016/j.biosx.2023.100375>
23. Ramesh, M., Janani, R., Deepa, C., Rajeshkumar, L.: Nanotechnology-Enabled Biosensors: A Review of Fundamentals, Design Principles, Materials, and Applications. *Biosensors.* 13, 40 (2022). <https://doi.org/10.3390/bios13010040>
24. Choi, W., Woo, G.H., Kwon, T.-H., Jeon, J.-H.: Obesity-Driven Metabolic Disorders: The Interplay of Inflammation and Mitochondrial Dysfunction. *Int. J. Mol. Sci.* 26, 9715 (2025). <https://doi.org/10.3390/ijms26199715>
25. Hossain, A., Manik, M.H., Rakib, S., Mahmud, N., Khan, S., Ahsan, Z., Islam, M.S., Hossain, N., Akter, M.A.: Green nanotechnology for implantable biosensors: Biocompatibility and functional integration in medical applications. *Biosens. Bioelectron. X.* 27, 100678 (2025). <https://doi.org/10.1016/j.biosx.2025.100678>
26. Kulkarni, M.B., Ayachit, N.H., Aminabhavi, T.M.: Recent Advancements in Nanobiosensors: Current Trends, Challenges, Applications, and Future Scope. *Biosensors.* 12, 892 (2022). <https://doi.org/10.3390/bios12100892>
27. Lin, X., Vasanth, A., Ashok, A., Phan, H.-P., Koo, K.M., Amin, M.A., Kaneti, Y.V., Salomon, C., Hossain, M.S.A., Yamauchi, Y., Masud, M.K.: Nanoarchitectonics of point-of-care diagnostics for sweat biomarkers analysis. *Nano Mater. Sci.* 6, 647–671 (2024). <https://doi.org/10.1016/j.nanoms.2024.01.010>
28. Singh, N.B., Monjur, A., Kumar, B., Varshney, S., Susan, Md.A.B.H.: Revolutionizing healthcare with nanosensor technology. *RSC Adv.* 15, 38774–38810. <https://doi.org/10.1039/d5ra04412j>
29. Malode, S.J., Ali Alshehri, M., Shetti, N.P.: Nanomaterial-Based Electrochemical Sensors for the Detection of Pharmaceutical Drugs. *Chemosensors.* 12, 234 (2024). <https://doi.org/10.3390/chemosensors12110234>
30. Róžańska-Walędziak, A., Walędziak, M.: Unraveling the Complexity of Metabolic Disorders Through Biomarkers: A Focus on Obesity and Type 2 Diabetes Mellitus. *Biomedicines.* 13, 2443 (2025). <https://doi.org/10.3390/biomedicines13102443>
31. Obasi, D.C., Abba, J.N., Aniokete, U.C., Okoroh, P.N., Akwari, A.Ak.: Evolving Paradigms in Nutrition Therapy for Diabetes: From Carbohydrate Counting to Precision Diets. *Obes. Med.* 100622 (2025). <https://doi.org/10.1016/j.obmed.2025.100622>
32. Jin, X., Qiu, T., Li, L., Yu, R., Chen, X., Li, C., Proud, C.G., Jiang, T.: Pathophysiology of obesity and its associated diseases. *Acta Pharm. Sin. B.* 13, 2403–2424 (2023). <https://doi.org/10.1016/j.apsb.2023.01.012>
33. Ejemot-Nwadiaro, R.I., Betiang, P.A., Basajja, M., Uti, D.E.: Obesity and Climate Change: A Two-way Street with Global Health Implications. *Obes. Med.* 100623 (2025). <https://doi.org/10.1016/j.obmed.2025.100623>
34. Gkrinia, E.M.M., Belančić, A.: The Mechanisms of Chronic Inflammation in Obesity and Potential Therapeutic Strategies: A Narrative Review. *Curr. Issues Mol. Biol.* 47, 357 (2025). <https://doi.org/10.3390/cimb47050357>
35. Mohiuddin, M.S., Neha, N.T., Mahir, J.U.K., Shakib, F.A.F., Alam, M.A., Wahiduzzaman, M., Barua, R., Shimu, S.J., Rahman, M., Hossain, M.R., Shariare, M.H., Mohib, M.M., Uddin, M.B.: Metabolic dysfunction associated fatty liver disease and type 2 diabetes: pathophysiological links, epidemiological trends, and clinical implications. *Front. Endocrinol.* 16, (2025). <https://doi.org/10.3389/fendo.2025.1669478>
36. Blüher, M.: Adipokines – removing road blocks to obesity and diabetes therapy. *Mol. Metab.* 3, 230–240 (2014). <https://doi.org/10.1016/j.molmet.2014.01.005>

37. Yan, Y., Cai, H., Yang, M.: The Application of Nanotechnology for the Diagnosis and Treatment of Endocrine Disorders: A Review of Current Trends, Toxicology and Future Perspective. *Int. J. Nanomedicine*. 19, 9921–9942 (2024). <https://doi.org/10.2147/IJN.S477835>
38. Gupta, A., Shah, K., Gupta, V.: Interconnected epidemics: obesity, metabolic syndrome, diabetes and cardiovascular diseases—insights from research and prevention strategies. *Discov. Public Health*. 22, 106 (2025). <https://doi.org/10.1186/s12982-025-00496-8>
39. Różańska-Wałędziak, A., Wałędziak, M.: Unraveling the Complexity of Metabolic Disorders Through Biomarkers: A Focus on Obesity and Type 2 Diabetes Mellitus. *Biomedicines*. 13, 2443 (2025). <https://doi.org/10.3390/biomedicines13102443>
40. Choi, J., Jang, S., Yu, S., Ahn, Y.-R., Kim, M., Lee, H., Kim, H.-O.: Microneedle–nanoparticle hybrid platforms for metabolic syndrome: advances in point-of-care diagnostics and transdermal therapeutics. *Discov. Nano*. 20, 193 (2025). <https://doi.org/10.1186/s11671-025-04376-7>
41. Bhatia, D., Paul, S., Acharjee, T., Ramachairy, S.S.: Biosensors and their widespread impact on human health. *Sens. Int.* 5, 100257 (2024). <https://doi.org/10.1016/j.sintl.2023.100257>
42. Mohanan, N.K., Mohanan, N.S., Sukumaran, S.M., Dhanya, T.M., Pillai, S.S., Rajan, P.K., Pillai, S.S.: An Insight into the Disease Prognostic Potentials of Nanosensors. *Inorganics*. 13, 259 (2025). <https://doi.org/10.3390/inorganics13080259>
43. Alum, E.U.: Optimizing patient education for sustainable self-management in type 2 diabetes. *Discov. Public Health*. 22, 44 (2025). <https://doi.org/10.1186/s12982-025-00445-5>

CITE AS: Kato Jumba K. (2026). Nano-Biosensors for Early Diagnosis and Continuous Monitoring of Obesity-Linked Metabolic Disorders. NEWPORT INTERNATIONAL JOURNAL OF PUBLIC HEALTH AND PHARMACY,7(1):56-61.
<https://doi.org/10.59298/NIJPP/2026/715661>